

SUPPLEMENTAL DIGITAL CONTENT 4

Confirmed Virologic Withdrawals Through the Week 96 Analysis Window

| Week of failure confirmation | Baseline CD4+, cells/mm ³ | Time between SVW and CVW, day | Viral loads at baseline / SVW / CVW / and withdrawal, copies/mL | Resistance mutations | | Fold change at baseline and CVW |
|------------------------------|--------------------------------------|-------------------------------|---|------------------------------|---------------------------|------------------------------------|
| | | | | Baseline | SVW | |
| 2DR | | | | | | |
| Week 16 | 212 | 7 | 124,492 / 6648 / 56,435 / 95 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.67, 0.72 3TC, 1.13, 1.12 |
| Week 24 | 284 | 28 | 50,263 / 348 / 206 / 96 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.76, 0.7 3TC, 0.98, 0.69 |
| Week 24 | 19 | 23 | 368,439 / 212 / 376 / 362 | NRTI: none INSTI: G193G/E | NRTI: none INSTI: none | DTG, 0.88, 0.86 3TC, 1.02, 1.43 |
| Week 24 | 213 | 27 | 96,277 / 451 / 9602 / 67 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.92, 0.8 3TC, 1.16, 1.16 |
| Week 24 | 529 | 34 | 17,232 / 461 / 251 / 59 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.81, 0.87 3TC, 1.17, 1.09 |
| Week 48 | 414 | 22 | 37,701 / 43,908 / 38,457 ^a | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.8, 0.79 3TC, 0.9, 1.74 |
| Week 60 | 347 | 101 | 101,671 / 703 / 85,556 ^a | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.89, 1.13 3TC, 0.95, 0.87 |
| Week 60 | 567 | 21 | 7654 / 3972 / 3131 / 1513 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.7, 0.71 3TC, 0.86, 0.86 |
| Week 72 | 50 | 14 | 63,817 / 422 / 2154 / 115 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.64, 0.81 3TC, 0.84, 0.69 |
| Week 72 | 74 | 27 | 112,812 / 61,076 / 87,794 / 671 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.84, 0.9 3TC, 0.84, 0.73 |

| | | | | | | |
|-----------------------|-----|----|-------------------------------------|------------------------------|------------------------------|---|
| Week 108 ^b | 317 | 31 | 341,818 / 396 / 726 / 280 | NRTI: none INSTI: L74I | NRTI: none INSTI: L74I | DTG, 0.72, 0.83 3TC, 1.09, 1.04 |
| 3DR | | | | | | |
| Week 12 | 22 | 28 | 136,753 / 393 / 276 ^c | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.95, 1.03 TDF, 0.98, 0.99 FTC, 0.86, 1.10 |
| Week 24 | 226 | 27 | 10,930 / 1136 / 809 / 264 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.72, NR TDF, 1, 0.81 FTC, 0.92, 0.95 |
| Week 24 | 251 | 30 | 76,325 / 569 / 362 / <50 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 0.68, 1.38 TDF, 0.95, 0.61 FTC, 1.13, 0.67 |
| Week 24 | 201 | 28 | 156,701 / 213 / 1559 / 97 | NRTI: none INSTI: none | NRTI: none INSTI: NR | DTG, 0.9, NR TDF, 1.04, 1.07 FTC, 0.97, 1.01 |
| Week 48 | 602 | 83 | 1568 / 8384 / 3653 / 3011 | NRTI: K70K/E INSTI: G193E | NRTI: none INSTI: G193G/E | DTG, 1.05, 1.05 TDF, 0.76, 0.77 FTC, 1.14, 1.28 |
| Week 72 | 253 | 16 | 668,811 / 254 / 232 / 121 | NRTI: none INSTI: none | NRTI: none INSTI: none | DTG, 1.13, NR TDF, 0.71, NR FTC, 0.68, NR |
| Week 96 | 144 | 40 | 28,905 / 30,316 / 7793 ^a | NRTI: none INSTI: L74I | NRTI: none INSTI: L74I | DTG, 0.68, 0.78 TDF, 0.82, 0.82 FTC, 1.07, 0.95 |

CVW, confirmed virologic withdrawal; 2DR, 2-drug regimen (dolutegravir + lamivudine); 3DR, 3-drug regimen (dolutegravir + tenofovir disoproxil fumarate/emtricitabine); DTG, dolutegravir; FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; NR, not reported because of assay failure; NRTI, nucleoside reverse transcriptase inhibitor; SVW, suspected virologic withdrawal; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.

^aParticipant met CVW at the withdrawal visit; no subsequent visit occurred. ^bParticipant met SVW criteria within the Week 96 window, with confirmatory viral load at Week 108. ^cParticipant met the criteria for CVW at Week 12 but was not reported at the Week 48 analysis because of a laboratory reporting error identified after the Week 48 analysis. This participant was not withdrawn as per protocol at the time and has been allowed to continue in the study (the participant has maintained virologic suppression from Week 24 through Week 108).